Tag: 贵族宝贝WUD

first_img About the Author Reprints Ed Silverman Alex Hogan/STAT [email protected] @Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Tags Donald Trumpdrug pricingpharmaceuticalsSTAT+ What is it? Pharmalot A Trump administration proposal to require drug makers to advertise prices in television ads could dissuade consumers from considering pricey medicines, according to a new study. But this reaction was mitigated when ads mentioned some patients may be able to receive the treatment for nothing, which is language that drug makers are pushing to include in the White House scheme.The researchers showed five different ads to 580 people about a fictitious diabetes drug. One ad did not mention price, another indicated the drug cost $50 a month, and still another cited $15,500 a month. Two other ads also mentioned each price, respectively, but added a line that “eligible patients” may be able to get the drug for as little as $0 a month, according to the study in JAMA Internal Medicine.center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Trump plan to force drug makers to advertise prices might work, but not if pharma gets its way Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED By Ed Silverman Jan. 23, 2019 Reprints Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. GET STARTED Log In | Learn More What’s included?last_img read more